Constitutive and Treatment-Induced CXCL8-Signalling Selectively Modulates the Efficacy of Anti-Metabolite Therapeutics in Metastatic Prostate Cancer


Autoria(s): Wilson, Catherine; Maxwell, Pamela J; Longley, Daniel B; Wilson, Richard H; Johnston, Patrick G; Waugh, David J J
Data(s)

01/05/2012

Resumo

<p>Background: The current study was undertaken to characterize the effect of anti-metabolites on inducing CXCL8 signaling and determining whether the constitutive and/or drug-induced CXCL8 signaling in metastatic prostate cancer (CaP) cells modulates their sensitivity to this class of agent.</p> <p>Methods: The response of metastatic CaP cells to 5-Fluorouracil (5-FU), Pemetrexed or Tomudex was determined using cell count assays, flow cytometry and PARP cleavage analysis. Quantitative-PCR, ELISA and immunoblots were employed to determine effects of drugs or CXCL8 administration on target gene/protein expression.</p> <p>Results: Administration of 5-FU but not pemetrexed potentiated CXCL8 secretion and increased CXCR1 and CXCR2 gene expression in metastatic PC3 cells. Consistent with this, the inhibition of CXCL8 signaling using a CXCR2 antagonist, AZ10397767, increased the cytotoxicity of 5-FU by 4-fold (P,0.001), and increased 5-FU-induced apoptosis in PC3 cells (P,0.01). In contrast, while administration of AZ10397767 had no effect on the sensitivity of pemetrexed, the CXCR2 antagonist exerted the greatest effect in increasing the sensitivity of PC3 cells to Tomudex, a directed thymidylate synthase (TS) inhibitor. Subsequent experiments confirmed that administration of recombinant human CXCL8 increased TS expression, a response mediated in part by the CXCR2 receptor. Moreover, siRNA-mediated knockdown of the CXCL8-target gene Bcl-2 increased the sensitivity of PC3 cells to 5-FU.</p> <p>Conclusions: CXCL8 signaling provides a selective resistance of metastatic prostate cancer cells to specific anti-metabolites by promoting a target-associated resistance, in addition to underpinning an evasion of treatment-induced apoptosis. © 2012 Wilson et al.</p>

Formato

application/pdf

Identificador

http://pure.qub.ac.uk/portal/en/publications/constitutive-and-treatmentinduced-cxcl8signalling-selectively-modulates-the-efficacy-of-antimetabolite-therapeutics-in-metastatic-prostate-cancer(43adcc2d-d215-442b-980e-3bedfd5e63de).html

http://dx.doi.org/10.1371/journal.pone.0036545

http://pure.qub.ac.uk/ws/files/5449789/Constitutive_and_Treatment_Induced_CXCL8.pdf

Idioma(s)

eng

Direitos

info:eu-repo/semantics/openAccess

Fonte

Wilson , C , Maxwell , P J , Longley , D B , Wilson , R H , Johnston , P G & Waugh , D J J 2012 , ' Constitutive and Treatment-Induced CXCL8-Signalling Selectively Modulates the Efficacy of Anti-Metabolite Therapeutics in Metastatic Prostate Cancer ' PLoS ONE , vol 7 , no. 5 , e36545 . DOI: 10.1371/journal.pone.0036545

Palavras-Chave #/dk/atira/pure/subjectarea/asjc/1100 #Agricultural and Biological Sciences(all) #/dk/atira/pure/subjectarea/asjc/1300 #Biochemistry, Genetics and Molecular Biology(all) #/dk/atira/pure/subjectarea/asjc/2700 #Medicine(all)
Tipo

article